A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer

► This is the first prospective multi-institutional study to evaluate paclitaxel plus carboplatin combination for metastatic or recurrent cervical cancer. ► This regimen provided a promising response rate of 59%, median PFS of 5.3 months, and median OS of 9.6 months. ► Toxicities of this regimen were well-tolerated and feasible regimen in outpatient setting.